Lung Transplant — Cost, Top Hospitals & Success Rates | MyMedicPlus

Lung transplantation is a life-saving surgical procedure in which one or both diseased, failing lungs are replaced with healthy lungs from a deceased donor. It remains the definitive treatment for selected patients with end-stage pulmonary disease whose condition cannot be adequately managed with medical therapy and who face a projected survival of less than 2–3 years without transplantation.

The International Society for Heart and Lung Transplantation (ISHLT) registry reports over 70,000 adult lung transplants performed globally since 1985, with volumes increasing annually. Median post-transplant survival is approximately 5.5 years overall, but highly varies by underlying disease: patients transplanted for idiopathic pulmonary fibrosis (IPF) have median survival of approximately 4.5 years, while those with cystic fibrosis (CF) survive a median of nearly 8 years after transplant.

Organ allocation in the USA is governed by the Lung Allocation Score (LAS), introduced in 2005, which prioritises patients by urgency and anticipated transplant benefit. Ex vivo lung perfusion (EVLP) is a key technological advance that allows assessment and reconditioning of marginal donor lungs, expanding the donor pool by up to 20%.

Lung transplantation is considered for patients with advanced, irreversible lung disease from a variety of causes:

• Chronic obstructive pulmonary disease (COPD) and emphysema — the single most common indication worldwide (~30% of lung transplants); includes alpha-1 antitrypsin deficiency emphysema
• Idiopathic pulmonary fibrosis (IPF) — rapidly progressive condition with poor prognosis; transplant is the only therapy proven to improve survival; approximately 25% of all lung transplants
• Cystic fibrosis (CF) — bilateral lung transplant is standard; excellent outcomes in carefully selected CF patients; approximately 16% of lung transplants
• Pulmonary arterial hypertension (PAH) — bilateral lung or heart-lung transplant for idiopathic or heritable PAH failing medical therapy; approximately 3–5%
• Sarcoidosis — advanced pulmonary sarcoidosis with respiratory failure; may recur in the graft (approximately 5%)
• Bronchiectasis (non-CF) — severe bronchiectasis from varied causes causing progressive respiratory failure
• Lymphangioleiomyomatosis (LAM) — rare disease almost exclusively in women of childbearing age; well-selected patients have excellent post-transplant outcomes
• Obliterative bronchiolitis — post-infectious or post-bone marrow transplant obliterative airway disease
• Re-transplantation — for chronic lung allograft dysfunction (CLAD) in select centres; approximately 4% of all lung transplants

Listing criteria are defined by ISHLT consensus guidelines and individualised by the transplant team. Key considerations include:

• Disease-specific thresholds — for COPD: BODE index ≥7, FEV1 less than 20% predicted, hypoxaemia or hypercapnia; for IPF: DLCO less than 39%, desaturation on 6-minute walk test, rapid FVC decline; for CF: FEV1 less than 30% predicted with rapid decline, increasing hospitalisation, massive haemoptysis; for PAH: NYHA Class III–IV despite maximal medical therapy, 6MWT distance less than 350 m
• Age — generally up to 65 years for bilateral transplant; up to 70 years for single lung in selected patients; no absolute upper limit but physiological age and comorbidities are paramount
• Absolute contraindications — malignancy within 2 years (except non-melanoma skin cancer and early-stage lung cancer treated with curative intent); active cigarette smoking (minimum 6 months cessation); BMI greater than 35 kg/m²; uncontrolled systemic disease (HIV not on effective ART, active hepatitis B with cirrhosis, severe cardiac or renal dysfunction not amenable to combined transplant); active systemic infection; documented non-compliance with medical therapy
• Relative contraindications — BMI 30–35, age over 65, severe osteoporosis, mechanical ventilation (extracorporeal membrane oxygenation — ECMO as bridge is now accepted at specialist centres), prior thoracic surgery increasing technical complexity, Burkholderia cenocepacia infection in CF (strongly relative)
• Psychosocial requirements — strong social support network, demonstrated medical compliance, no active substance abuse, adequate cognitive function for complex post-transplant medication management

The type of lung transplant performed depends on the underlying disease, donor availability, and patient factors:

• Bilateral sequential lung transplant (BSLT) — the most commonly performed procedure, replacing both lungs sequentially through a clamshell or bilateral thoracotomy incision; preferred for CF (to eliminate infected native lung), PAH, younger patients with COPD; better long-term outcomes than single lung transplant for most indications
• Single lung transplant (SLT) — one lung is replaced; technically simpler, shorter waiting time, and allows one donor to benefit two recipients; preferred for older patients with IPF or emphysema where bilateral transplant risk is excessive; declining in use due to inferior long-term outcomes
• Heart-lung transplant (HLT) — simultaneous transplantation of heart and both lungs; reserved for Eisenmenger syndrome, PAH with refractory right heart failure, or combined end-stage heart and lung disease; limited by donor availability
• Living-donor lobar lung transplant (LDLLT) — lower lobes donated by two living donors (typically family members) are transplanted in place of the recipient's lungs; primarily used in Japan for paediatric patients due to deceased donor shortage; requires two healthy donors
• ECMO as bridge to transplant — venovenous (VV-ECMO) or venoarterial (VA-ECMO) can support critically ill patients awaiting donor lungs; increasingly accepted at specialised centres; allows ambulation and physiotherapy while awaiting transplant
• Ex vivo lung perfusion (EVLP) — marginal or extended criteria donor lungs are reconditioned on the Vivoline or OCS Lung device before transplantation; allows 15–20% increase in usable donor lungs

For patients with end-stage lung disease, transplantation provides benefits that cannot be achieved with any medical therapy:

• Survival benefit — transplant confers a significant survival advantage for IPF, CF, and PAH patients compared to those remaining on the waiting list; the benefit for COPD is less clear for the overall group but well established for those with very severe disease
• Resolution of respiratory failure — oxygen dependency is eliminated in the vast majority of recipients; pulmonary function (FEV1, DLCO, 6MWT) improves substantially in the first 6–12 months
• Dramatic quality-of-life improvement — most recipients move from housebound existence to functional independence; capacity for exercise, work, and social participation is restored
• Cure of underlying structural disease — the transplanted lungs are free of the original disease; for conditions like CF, genetically abnormal airways are replaced with normal donor lung tissue
• Psychological benefit — resolution of progressive breathlessness and end-of-life anxiety has a profound positive impact on mental health and family wellbeing

Lung transplantation is the highest-risk solid organ transplant procedure, with a significant burden of early and late complications:

• Primary graft dysfunction (PGD) — the most serious early complication; severe PGD (Grade 3 at 72 hours) occurs in 10–25% of recipients and is the leading cause of early mortality and a risk factor for subsequent CLAD; manifests as acute hypoxaemia with bilateral infiltrates on CXR
• Chronic lung allograft dysfunction (CLAD) — the leading cause of late mortality; encompasses bronchiolitis obliterans syndrome (BOS, obstructive phenotype) and restrictive allograft syndrome (RAS); affects up to 50% of recipients by 5 years; treatment options are limited (augmented immunosuppression, azithromycin, extracorporeal photopheresis, retransplantation)
• Acute cellular rejection (ACR) — occurs in 15–25% of recipients, predominantly in the first year; treated with high-dose methylprednisolone; persistent or recurrent ACR increases CLAD risk
• Antibody-mediated rejection (AMR) — increasingly recognised; treated with plasmapheresis, IVIG, rituximab; associated with worse outcomes
• Infections — leading cause of morbidity and mortality in the first year; bacterial pneumonia, CMV (commonest viral pathogen), aspergillus (high mortality in lung transplant), PCP (Pneumocystis jirovecii), and community respiratory viruses (influenza, RSV, SARS-CoV-2); prophylactic regimens significantly reduce but do not eliminate risk
• Anastomotic complications — bronchial anastomotic dehiscence (1–2%) or stenosis (5–10%) requiring bronchoscopic intervention (balloon dilation, stenting)
• Calcineurin inhibitor nephrotoxicity — chronic kidney disease affects up to 40% of lung transplant recipients at 5 years; end-stage renal disease requiring dialysis or kidney transplant occurs in approximately 5%
• Post-transplant malignancy — post-transplant lymphoproliferative disorder (PTLD) and skin cancers are most common; risk is amplified by intensity of immunosuppression

Lung transplant recipients require the most intensive long-term monitoring of any solid organ transplant:

• ICU care — recipients are typically ventilated for 24–72 hours post-operatively; weaning strategy and bronchoscopy to assess anastomoses are performed within 24–48 hours; median ICU stay is 7–14 days
• Inpatient rehabilitation — early mobilisation and physiotherapy are critical to prevent muscle deconditioning; pulmonary rehabilitation begins in hospital and continues as an outpatient
• Immunosuppression protocol — standard triple therapy: tacrolimus (or cyclosporine), mycophenolate mofetil, and prednisone; azithromycin 250 mg three times weekly is added for its anti-inflammatory and CLAD-preventive properties; immunosuppression is lifelong
• Surveillance bronchoscopy — protocol bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial biopsy at 1, 3, 6, and 12 months; additional bronchoscopy for any decline in FEV1 or clinical deterioration
• Pulmonary function monitoring — home spirometry (FEV1 measurements twice daily) is standard practice; a sustained decline of greater than 10–15% from baseline triggers urgent evaluation for CLAD or infection
• Cardiovascular and metabolic surveillance — annual echocardiogram; lipid panel, glucose, and blood pressure monitoring for immunosuppression-related metabolic complications
• Cancer surveillance — annual skin examination; annual CT chest (baseline and for cancer screening); colonoscopy per population guidelines accelerated by 5-year intervals post-transplant
• Vaccination — annual influenza vaccine; pneumococcal, hepatitis B, and zoster vaccines per immunocompromised patient guidelines; live vaccines are contraindicated

Lung transplantation is among the most expensive medical procedures in the world. Costs include the transplant procedure itself, the initial hospitalisation, and lifelong post-transplant management:

• India — $35,000–$75,000 for bilateral lung transplant; leading centres include Apollo Hospitals (Hyderabad, Chennai), Fortis (Gurgaon), and Medanta; India performs approximately 100–150 lung transplants annually, mostly at high-volume centres with experienced thoracic surgery teams
• South Korea — $80,000–$130,000; Asan Medical Center and Samsung Medical Center perform high-volume lung transplants with excellent outcomes data
• Germany — €100,000–€180,000; Hannover Medical School (Medizinische Hochschule Hannover) is Europe's largest lung transplant centre and a global reference
• United Kingdom — publicly funded on the NHS for UK residents; private cost £150,000–£250,000; Harefield Hospital and Royal Papworth Hospital are specialist centres
• United States — $500,000–$900,000 for the transplant episode alone; annual post-transplant care (immunosuppression, surveillance, hospital admissions) adds $50,000–$100,000 per year

Key cost drivers: single vs bilateral transplant, use of ECMO as bridge or during surgery, ICU duration, infectious complications, and immunosuppression costs. Tacrolimus, mycophenolate, and prednisone cost approximately $1,000–$2,500 per month. International patients must also plan for long-term follow-up — transplant centres require regular in-person visits for at least the first year, favouring proximity to the transplanting centre.

Alternatives to transplantation are appropriate as definitive therapy in milder disease or as bridging/complementary strategies:

• Long-term oxygen therapy (LTOT) — reduces mortality in hypoxaemic COPD (PaO2 less than 55 mmHg); improves quality of life; does not halt disease progression
• Antifibrotic therapy for IPF — pirfenidone and nintedanib slow FVC decline by approximately 50% and may modestly extend survival; do not reverse established fibrosis; used as bridge to transplant in eligible patients
• Targeted therapies for PAH — phosphodiesterase-5 inhibitors (sildenafil), endothelin receptor antagonists (macitentan, ambrisentan), prostanoids (epoprostenol IV, treprostinil), and soluble guanylate cyclase stimulators (riociguat); combination therapy can delay transplant by years in some patients
• Lung volume reduction surgery (LVRS) — for upper-lobe predominant emphysema with low exercise capacity after rehabilitation; NETT trial demonstrated survival and quality-of-life benefit in carefully selected patients; considered an alternative to or bridge before transplantation
• Bronchoscopic lung volume reduction (BLVR) — endobronchial valves (Zephyr, Spiration) provide minimally invasive lung volume reduction in heterogeneous emphysema; clinically meaningful improvement in FEV1, 6MWT, and quality of life; less invasive than surgery or transplant
• Pulmonary rehabilitation — structured exercise training, education, and psychosocial support; improves exercise capacity and quality of life in moderate-to-severe COPD and IPF; does not alter transplant candidacy but optimises pre-transplant conditioning
• Palliative care — for patients not suited to transplantation or who decline; focuses on breathlessness management (opioids, benzodiazepines, fans), advance care planning, and family support